Please assess the completion status of the following clinical trial:

Trial Title: Spinal Cord Stimulation in Small Fibre Neuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* SFN diagnosis according to international criteria,~* Age between 18 and 75 years, lucid,~* Mean pain intensity during daytime or night-time should be 5 or higher on the 11-points numeric rating scale (NRS),~* The pain intended to treat has been present for more than 12 months, as declared by patients to the best of their knowledge or after studying available medical records,~* Previous treatment has been unsuccessful (insufficient pain relief and/or unacceptable side-effects) with drugs from the following drug categories~  * Tricyclic anti-depressant agent (e.g., Amitriptyline)~ * Alpha 2-delta calcium channel agonist/Anti-epileptic drugs (e.g. Pregabalin (Lyrica) or Gabapentin (Neurontin)),~ * Serotonin-norepinephrine reuptake inhibitors (e.g., Duloxetine (Cymbalta)),~ * Tramadol or strong opioids.~* Patients will have to be treated or have been treated with at least 3 drugs from the above mentioned drug categories according to the EFNS guidelines for neuropathic pain \[34\]. Starting dosage is based on individual patient characteristics. Each drug has to be tried for at least 3 weeks and dose will have to be raised once, if possible. Drug treatment can be stopped due to insufficient pain relief and/or unacceptable adverse events.~* Patients will have to be in steady state in medication use for at least 2 months prior to inclusion.~Exclusion Criteria:~* Neuromodulation in history,~* Neuropathic pain prevalent in the upper limbs (UL) compared to the legs; UL NRS not exceeding 3)~* Neuropathy or chronic pain of other origin than SFN (NRS \> 3),~* Addiction: drugs, alcohol (5E / day) and/or specific medication~  * Drugs: cocaine, heroin, marihuana,~ * Alcohol: wine, beer, liquor,~ * Medication: benzodiazepines.~* Insufficient cooperation from the patient (little motivation, understanding or communication problems),~* Blood clotting disorder or the use of oral anticoagulation that cannot be stopped for a period of 10 days around the implantation procedure.~* Immune deficiency (HIV-positive if known, corticosteroids with a dose equivalent to \> prednisolone 10 mg, immunosuppressive medication, etc.)~* Known peripheral vascular disease, no palpable peripheral pulsations at the feet (inclusion is possible if pulsations are absent, but ankle/brachial index is between 0.7 and 1.2 in both feet)~* Life expectancy \< 1 year~* Pacemaker~* Local infection or other skin disorders at site of incision~* Other clinically significant or unstable, or severe acute or chronic medical or psychiatric/psychological condition or laboratory abnormality that may increase the risk associated with study participation or procedure or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.~* Pregnancy~* Severe cardiac or pulmonary failure (\> NYHA classification II)~* Use of opioids (higher dose than an equivalent of 30 mg morphine a day)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Spinal cord stimulation (Type: EXPERIMENTAL): implantation of spinal cord stimulator

Based on this trial design, predict the completion outcome and termination type (if applicable).